Daniel E Geffken insider trades: Eloxx Pharmaceuticals (ELOX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Daniel reports to the SEC
and 2 more companies
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 29, 2021 | ELOX | ↑ Buy | 50,000 | $0.72 | $36K | Direct | Dec 1, 2021 (2d) |
| May 22, 2020 | WINT | ↑ Buy | 2,069 | $7.25 | $15K | Direct | May 27, 2020 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Daniel E Geffken's insider trades
Daniel E Geffken is Interim CFO at Eloxx Pharmaceuticals (ELOX). Since May 22, 2020, Daniel has reported 2 open-market purchases worth $51K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), other transactions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ELOX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.